Oyinlola Jessie O, Beloueche-Babari Mounia, Frysz Monika, Yelland Eleanor, Walker Amy, Williams Rachael, Jones Robin L
Clinical Practice Research Datalink (CPRD), Safety and Surveillance Group, Medicines and Healthcare Products Regulatory Agency, London, UK.
Boehringer Ingelheim Ltd, Bracknell, UK.
Rare Tumors. 2025 Jul 26;17:20363613251346621. doi: 10.1177/20363613251346621. eCollection 2025.
This real-world data study evaluates demographic and clinical characteristics and survival in patients with liposarcoma to inform our understanding of treatment patterns and associated outcomes in this rare cancer. A retrospective cohort study was conducted using existing data available through the Clinical Practice Research Datalink. Male and female patients aged 18 years or older who had their first ever record of liposarcoma between 1998 and 2018 were included in the study. The demographic and tumour characteristics were presented (overall, by first line treatment and for dedifferentiated liposarcoma only) as proportions (percentages) while continuous variables were presented as means with standard deviation and interquartile ranges. Survival rates from diagnosis date and first line treatment (with 95% confidence intervals) were also calculated. 1,315 patients were included, of which 46% (611) had a treatment recorded. Most patients were male and over the age of 60 years. Surgery was the most frequent treatment received following diagnosis (34% of all patients), followed by radiotherapy (8%) and chemotherapy (2.4%) with the remaining patients having no record of treatment available. Overall, there was a 77% probability of survival after diagnosis at 5 years. Findings from this study help advance our understanding of real world patient characteristics, treatment patterns and survival outcomes in a rare and heterogeneous cancer, which may be useful for guiding clinical management. This study also identified challenges with using real world data, which can be minimised through improving data collection and standardisation.
这项真实世界数据研究评估了脂肪肉瘤患者的人口统计学和临床特征以及生存率,以增进我们对这种罕见癌症的治疗模式及相关预后的了解。利用通过临床实践研究数据链可获取的现有数据进行了一项回顾性队列研究。纳入研究的是1998年至2018年间首次有脂肪肉瘤记录的18岁及以上男性和女性患者。人口统计学和肿瘤特征以比例(百分比)呈现(总体、按一线治疗以及仅针对去分化脂肪肉瘤),连续变量以均值加标准差和四分位数间距呈现。还计算了从诊断日期和一线治疗开始的生存率(95%置信区间)。共纳入1315例患者,其中46%(611例)有治疗记录。大多数患者为男性且年龄超过60岁。诊断后最常接受的治疗是手术(占所有患者的34%),其次是放疗(8%)和化疗(2.4%),其余患者无可用治疗记录。总体而言,诊断后5年的生存概率为77%。本研究结果有助于增进我们对一种罕见且异质性癌症的真实世界患者特征、治疗模式和生存结局的了解,这可能有助于指导临床管理。本研究还确定了使用真实世界数据存在的挑战,通过改进数据收集和标准化可将这些挑战降至最低。